Industry

Figures converted from Swiss francs at historical FX rates - see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged. Peer figures for Demant (DKK) and Amplifon (EUR) remain in their reporting currency because cross-rates are not available in this run; global market-size figures are already quoted in USD by the source.

Hearing Care: A Slow-Compounding Health Market Run by Five Manufacturers

Sonova makes hearing aids and cochlear implants and, increasingly, owns the shops that fit them. To understand the stock you first have to understand an unusual industry: a medical-device market with the demographics of a demographic megatrend but the adoption rate of a luxury good. More than 1.5 billion people worldwide live with some degree of hearing loss and over 400 million could benefit from a hearing aid, yet fewer than one in five of those who would benefit are actually treated [3] [4]. That single gap - huge need, low penetration - is the whole investment story: it is why the market grows through cycles, and why nobody has yet "won" it.

This tab builds the mental model an investor needs before reading the rest of the report: how big the pool is, who pays, how the five manufacturers compete, where new entrants (OTC devices, EssilorLuxottica, Apple) fit, and how to read the cycle Sonova is living through right now.

1. The industry in one screen

Sources: Demant A/S Annual Report 2025 - roughly USD 7bn wholesale and USD 20bn retail value, ~13m people fitted with ~23m hearing aids in 2025, 4-6% long-term value growth [1] [2] [5]; treatment rate under 20% [3].

Two numbers frame everything. The wholesale market - what manufacturers like Sonova collect for the device itself - is only about USD 7 billion a year. The retail market - what the end consumer pays once you add the audiologist's fitting, tuning, and years of after-care - is roughly USD 20 billion [1]. The gap between those two figures is the reason every major manufacturer is buying retail chains: the fitting and service layer is where the larger, stickier profit pool sits. That single fact explains most of the industry's strategy.

2. A structural-growth market, temporarily off its trend

The demand engine is demographics plus penetration. Populations are aging, hearing loss rises with age, and adoption is low almost everywhere - so both the number of users and the value per user can climb for decades. Manufacturers converge on a 4-6% per-annum value growth rate as the long-run trend, combining modest unit growth with rising average selling prices [5] [34].

The clearest way to see the opportunity is adoption by severity and geography. Even in the richest markets, only about two-thirds of people with severe loss wear a device - and adoption collapses toward single digits for mild loss and in emerging markets.

Source: Sonova strategy update, March 2026 - adoption by geography and severity (North America and Western Europe vs. Japan, China, India, Korea, Brazil, Mexico) [6].

Every unfilled bar above is latent demand. That is why the industry treats the growth algorithm as additive: the underlying market contributes roughly 3-5 points of annual growth, share gains from innovation and geographic expansion another 1-3 points, and bolt-on retail M and A a further 1-2 points - the arithmetic behind Sonova's 5-10% medium-term sales-growth target [9] [31].

But 2025 was a reminder that this is still a cyclical consumer-health market, not a utility. A hearing aid is a largely discretionary, big-ticket, often out-of-pocket purchase, so demand tracks consumer confidence. Through 2025 the market grew "at a slower pace than normal," which the incumbents attribute to macroeconomic uncertainty rather than any structural break [7]. Sonova now guides to only 2-4% market growth in its 2026/27 year, improving back toward the 3-5% mid-term trend as confidence recovers [8]. Reading where the market sits inside that 2-to-5 band is the single most important cyclical judgment for the whole sector.

3. How the value chain works - and why manufacturers are becoming retailers

Newcomers are often surprised that "hearing aid company" describes two very different businesses stapled together. Understanding the four tiers below is the key to the economics.

Sources: Sonova describes itself as vertically integrated across Wholesale, Retail and Cochlear Implants [10]; wholesale is R and D-intensive while the retail market is mostly independently owned [11]; government channels and bundled pricing [12]; OTC in selected markets [12].

The wholesale business is a technology race: a handful of specialised firms compete on chips, algorithms and battery life, and market position is underpinned by heavy, sustained R and D [11]. The retail business is the opposite: highly fragmented, local, relationship-driven, with the majority of the world's hearing-aid clinics still independently owned [11]. That fragmentation is the prize. For over a decade the industry has consolidated distribution, with larger players buying smaller chains - and when a manufacturer buys a clinic it captures both margins and locks in a channel for its own devices [19]. This is why Sonova, Demant and others describe themselves as "vertically integrated": they design the aid, own the store, and increasingly own the customer relationship [10].

A fourth tier sits on top of the government channel and matters more than its size suggests: bulk institutional buyers. In the US, the Department of Veterans Affairs (VA) is one of the largest single hearing-aid buyers in the world, and share swings there move manufacturer results - Sonova's rechargeable custom device took roughly 60% of the VA in-the-ear segment, pushing its overall VA share to a five-year high [13]. The UK NHS plays a similar role in Europe [12].

4. The competitive arena: an oligopoly of five, plus one giant retailer

Globally, five manufacturers make the overwhelming majority of prescription hearing aids: Sonova (Phonak, Unitron), Demant (Oticon), WS Audiology (Widex + Signia), GN (ReSound) and Starkey. It is a classic technology oligopoly - high R and D, fresh silicon every two years, and share that shifts with the product cycle. Alongside them sits Amplifon, the one pure-play retailer large enough to matter, and Costco, whose warehouse channel is large enough that losing shelf space there dents a manufacturer's US numbers.

Sources: Sonova revenue converted to USD and reported EBIT margin from company financials (FY2024/25 sales ~$4,266m); Demant revenue DKK 22,971m and 17.2% EBIT margin before special items [16] [17]; Amplifon revenue EUR 2.4bn and 22.6% adjusted-EBITDA margin [15]. Margins are not strictly comparable (EBIT vs. adjusted EBITDA) and currencies differ; WS Audiology, GN and Starkey have no filing in the corpus.

The peer picture teaches three things. First, scale is similar at the top: Sonova (~$4.3bn) and Demant (DKK ~23bn, roughly $3.4bn) are close in size, so leadership is decided by product cycles, not balance sheets. Second, the retail land-grab is real and accelerating: Demant's 2025 KIND acquisition in Germany added a national clinic network and lifted its clinic count above 4,500 while adding ~3,000 employees [18], and Amplifon operates 5,630 owned clinics across 26 countries for a 13% global retail share [14]. Third, margins are structurally high - high-teens to low-20s EBIT for manufacturers and mid-20s adjusted EBITDA for the retailer - because branded medical devices plus a fitting service command real pricing power. Demant grew only ~2% organically in 2025, partly because it lost share at a large US retailer, a vivid illustration of how concentrated the channel risk is [16].

Barriers to entry are high but not absolute. Making a modern hearing aid now means running deep neural networks and AI on a proprietary chip small enough to sit behind an ear, which requires the kind of sustained R and D only a handful of firms can fund [11]. On top of that sit medical-device regulation, clinical validation, and decades-old relationships with audiologists and government buyers. The moat is real - which is exactly why the disruption threat comes from outside the industry.

5. The disruption question: OTC, EssilorLuxottica and Apple

In August 2022 the US FDA created a new over-the-counter (OTC) category, letting adults with perceived mild-to-moderate loss buy self-fitting hearing aids without a prescription or an audiologist [20]. The bear fear was commoditisation: cheap consumer devices collapsing the incumbents' prices. Three years on, the incumbents' framing is more nuanced - and, so far, supported by the data they cite: OTC take-up has not come at the expense of traditional prescription aids but appears to be expanding the overall market by pulling in first-timers who would never have visited a clinic [21]. Sonova itself sells OTC devices in the US, China and Japan [12].

The more interesting entrants are the ones with distribution the incumbents lack:

• EssilorLuxottica, the eyewear giant, received FDA clearance in February 2025 for Nuance Audio - hearing-enhancing glasses aimed at mild-to-moderate loss - and put them into roughly 15,000 stores across twelve markets by year-end [22] [23]. That is a retail footprint no hearing-aid maker can match, aimed squarely at the mild-loss customers the industry has never converted.
• Apple and Sony have brought hearing features into consumer earbuds and headphones, normalising the category and softening stigma - a tailwind for penetration even where it is competition for the low end.

The strategic read: OTC and consumer entrants are most dangerous at the mild end and most helpful as stigma-reducers and market-expanders for the medically-fit prescription core where the incumbents' audiology and reimbursement moats still hold. Tellingly, Sonova concluded its own consumer-audio bet was non-core and decided in March 2026 to divest its Consumer Hearing business and refocus on medical hearing care [24].

6. Reading the cycle: product launches, COVID, China and the franc

Because the top five are so evenly matched, share is won and lost on the product cycle. A leading platform launch can swing several points of market share within quarters; being late costs share just as fast. Sonova's recent run shows the mechanism cleanly:

Source: Sonova reported financials, FY2021-FY2026, converted to USD at fiscal-year-end rates; FY2026 reflects continuing operations after the Consumer Hearing business was reclassified as discontinued [24]. Foreign-exchange effects reduced FY2025-26 reported sales by about $279m, or 6.1 points of growth [28].

Source: Sonova reported financials, FY2021-FY2026 (statutory EBIT margin; management's normalized adjusted-EBITA margin recovered to ~22.5% by FY2025/26).

Four forces explain that shape, and each is an industry lesson:

1. The COVID whipsaw. Hearing care is elective. Lockdowns shut clinics and postponed cochlear-implant surgery, then demand snapped back - Sonova's cochlear-implant sales rebounded +51.7% in FY2021/22 as elective procedures resumed [29]. It is the sharpest recent reminder that this is a deferrable purchase.
2. The product cycle. The Phonak Audeo Infinio / Sphere Infinio launch in August 2024 - built around a dedicated AI sound-processing chip - drove "significant market share gains," and the follow-on Virto R and Infinio Ultra extended the lead into 2025/26 [25]. Launch years also compress margins first (launch and lead-generation spend) before share and operating leverage arrive - visible in the 2024-25 margin dip.
3. China and reimbursement policy. China's roll-out of volume-based procurement (VBP) - government bulk-tendering that forces prices down - hammered the cochlear-implant segment, where system sales fell 10.3% in local currency, essentially all of it China [26]. Reimbursement design is a first-order industry risk, not a footnote.
4. The currency overlay. Sonova reports in Swiss francs but earns in dollars, euros and yen, so a strong franc is a permanent reported-growth headwind - it clipped 6.1 points off FY2025/26 reported sales [28]. For any Swiss-listed device maker, local-currency growth is the number that matters.

Leadership turnover is part of the cycle too: Sonova's CEO stepped down in 2025 and was replaced by Eric Bernard, formerly CEO of competitor WS Audiology - a sign of how small and interconnected this five-firm world is [27].

7. Who pays, and who regulates

Because most of the bill is split between the consumer and an insurer or government scheme, reimbursement policy sets the ceiling on price and volume in every country [12]. The models differ sharply: the US mixes private pay, managed-care benefits and the VA; the UK runs the NHS as a near-universal free provider; Germany and much of Europe use statutory-insurance subsidies at a fixed reimbursement; China increasingly uses VBP tenders. A policy change in any one - a reimbursement cut, an NHS re-tender, a VBP round - can reprice a whole national market overnight.

On the product side, hearing devices are regulated medical devices, which is both a cost and a moat:

• Prescription and OTC hearing aids clear the FDA as Class I / Class II devices and, in Europe, must meet the EU Medical Device Regulation 2017/745 (with the newer MDR raising the clinical-evidence and documentation burden) [32].
• Cochlear implants are surgically implanted and sit in the highest risk tier - Class III in the US, requiring full FDA pre-market approval - which is why that segment has few credible competitors and long product cycles [33].

Product quality is a live operating risk, not a given: as the mix shifts toward customised in-the-ear devices, Sonova's hearing-instrument reliability rate actually slipped 6.6% year-on-year, a reminder that manufacturing execution feeds directly into warranty cost and brand [35].

8. Where the industry is heading - and the watchlist

The incumbents' shared bet is that the growth algorithm holds: a 3-5% market compounding on low penetration, topped up by share gains and retail M and A. Sonova has put a number on it - a CHF 6 billion (about $7.6 billion) revenue ambition by FY2030/31 (up from ~$4.5bn today), implying 5-10% annual sales growth and 7-12% Core EBIT growth [30] [31]. Whether that is credible is the question the rest of this report exists to answer. Here is what to watch to keep score.

Source: synthesis of the cited filings above; see the market-growth guidance [8], China VBP impact [26] and the CHF 6bn ambition [30].

The one-paragraph mental model. Hearing care is a high-margin medical-device oligopoly of five manufacturers, wrapped in a fragmented retail market they are steadily buying up, selling into a customer pool that is enormous and barely penetrated. It grows 3-5% through the cycle on aging demographics and rising penetration, with an extra point or two from share and M and A - but it is discretionary enough to wobble when consumers are nervous, and exposed to reimbursement policy and currency. The bull case is decades of penetration runway and pricing power; the bear case is a cyclical, big-ticket product facing new consumer-tech entrants and government price pressure. Sonova sits at the centre of it, leading the current product cycle and reaching for CHF 6 billion.